Enda Kenny (Mayo, Fine Gael) | Oireachtas source

I did not hear it say that. If the company is prepared to come a way down from €160,000 per year per patient, let us see what it is talking about. The NCPE estimates the cost-effective price at €30,000 per patient, the NCPE will be flexible with realism. However, I very strongly believe in what Professor Barry has pointed out, that the price estimated by the company is grossly excessive.

The Minister for Health, Deputy Simon Harris, has said that Vertex wants to meet with him and the HSE. The HSE is open to this and there will be realistic discussions with no animosity. The company has come in here, as it did in Australia, Scotland, England and Canada, where it was not approved on the public health bill. The price is excessive. If Deputies Micheál Martin and Billy Kelleher say the company is prepared to come way down, let us see the colour of its step. The HSE will be flexible in respect of the cystic fibrosis patients and will treat it with realism, but not at this cost.

See this speech in context